Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY



Status:Archived
Conditions:Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:May 2009
End Date:January 2020

Use our guide to learn which trials are right for you!

Trial of Allogeneic BMT for Hematologic Malignancies Using HLA-matched Related or Unrelated Donors With Fludarabine and IV Busulfan as Pre-transplant Conditioning Followed by Post-transplant Immunosuppression With High-dose Cyclophosphamide


The purpose of this research is to find the most effective and least toxic way to prevent
GVHD after BMT.


A person who has cancer of the blood or lymph glands can be treated by bone marrow
transplantation (BMT). BMT has developed over several decades of research on both animal
and human subjects as an effective treatment of various malignant and nonmalignant
hematologic diseases. Many hematologic malignancies can be successfully treated with a
combination of high-dose chemotherapy or chemo-radiotherapy and transplantation of
allogeneic bone marrow or peripheral blood stem cells (alloBMT)

However, a possible side effect of BMT is graft versus host disease (GVHD). GVHD occurs
when cells of the donor's immune system, which are present in the bone marrow, attack the
BMT recipient's normal tissue. Prevention of GVHD is important for the success of the bone
marrow transplant. This research is being done to find the most effective and least toxic
way to prevent GVHD after BMT


We found this trial at
3
sites
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Baltimore, Maryland 21231
410-955-6190
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins The name Johns Hopkins has become synonymous...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Seattle, Washington 98109
?
mi
from
Seattle, WA
Click here to add this to my saved trials